Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation - 2Tributes pour in for James Ransone, 'The Wire' actor who died at 46
- 3NAFFIC and Aware to Launch First China-Europe Digital Product Passport
- 4Insane Realities That Will Make You Reconsider How you might interpret History
- 5Underestimated Metropolitan Experience Urban communities On the planet
- I went to Japan during peak cherry blossom season and found an easy way to escape the crowds at popular tourist attractions
- No red, no long shorts: The fashion rules Joe Burrows lives by
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- Vote in favor of your Number one Kind of Gems
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- Surveys of 6 Hot Savvy Beds
- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- Conquering Social Generalizations: Individual Accounts of Strengthening
